secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cytek Biosciences, Inc. (CTKB)
CIK:        0001831915
Form:       8-K
Filed at:   2025-01-15T23:59:59+00:00
Accession:  0001193125-25-006599
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cytek Biosciences expects FY2024 revenue $200-201M, 4% growth; Q4 rev up 11-13% QoQ
--------------------------------------------------------------------------------

- Full-year 2024 revenue expected $200-201M, up 4% from $193M in 2023; ~$1M negative FX impact.
- Q4 2024 revenue $57-58M, 11-13% sequential growth, down 2% to flat YoY; FX reduced Q4 by ~$1.5M.
- CEO cites strong APAC and Rest of World growth, offset by order delays and USD strength.
- Preliminary results unaudited; full earnings and 2025 guidance expected late February 2025.
- Company to present at J.P. Morgan Healthcare Conference on January 16, 2025 in San Francisco.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831915/000119312525006599/0001193125-25-006599-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831915/000119312525006599/d914343d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-006599

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer